MMP-13 as a therapeutic target in breast cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/502622

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

MMP13 is upregulated in cancer cells and in the tissue that forms around the cancer (stroma). A new MMP13-specific inhibitor reduces breast cancer growth in a mouse model, both at the primary site and also in bone. We will determine the role of MMP13 made by the cancer cells and stroma, respectively, extend the inhibitor work, and identify proteins being cleaved by MMP13. Being a late-stage manifestation, bone metastasis may represent an important clinical trial setting for MMP inhibitors.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $537,579.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

breast neoplasms-pathology-therapy | cancer metastasis | control of tumour progression | enzyme inhibitors as pharmacologic agents | extracellular matrix | matrix metalloproteinases | mechanisms of growth invasion and metastasis | novel anticancer agents | therapy of breast cancer

Related Links